CAR-T cell therapy axicabtagene ciloleucel (Yescarta) is now funded for four types of non-Hodgkin lymphoma patients in select Australian public hospitals. From 5 August, selected patients with relapsed or refractory CD19-positive diffuse large B cell lymphoma (DLBCL), primary mediastinal large B cell lymphoma, transformed follicular lymphoma or high grade B cell lymphoma will be able ...
Second CAR T cell therapy gets public funding for B cell lymphomas
By Natasha Doyle
5 Aug 2021